The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies
Open accessAbstract
The cardiovascular system ensures the delivery of oxygen and nutrients to all cells, tissues, and organs. Under extended exposure to reduced oxygen levels, cells are able to survive through the transcriptional activation of a series of genes that participate in angiogenesis, glucose metabolism, and cell proliferation. The oxygen-sensitive transcriptional activator HIF-1 (hypoxia-inducible factor-1) is a key transcriptional mediator of the response to hypoxic conditions. The HIF-1 pathway was found to be a master regulator of angiogenesis. Whether the process is physiological or pathological, HIF-1 seems to participate in vasculature formation by synergistic correlations with other proangiogenic factors such as VEGF (vascular endothelial growth factor), PlGF (placental growth factor), or angiopoietins. Considering the important contributions of HIF-1 in angiogenesis and vasculogenesis, it should be considered a promising target for treating ischaemic diseases or cancer. In this review, we discuss the roles of HIF-1 in both physiological/pathophysiological angiogenesis and potential strategies for clinical therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Schematic representation of HIF-α gene structures and DNA binding. (a) HIF-1α and HIF-2α contain the following domains: a nuclear localisation domain (NLS), DNA binding and dimerisation domains (bHLH/PAS), oxygen-dependent degradation domain (ODDD), and cofactor interaction and transcriptional activity domains (N-TAD/C-TAD). HIF-3α lacks a C-TAD domain. NLS: nuclear localisation signal; bHLH: basic helix-loop-helix domain; PAS: Per-ARNT-Sim motif; ODDD: oxygen-dependent degradation domain; N-TAD: N-terminal transactivation domain; C-TAD: C-terminal transactivation domain. (b) Dimerisation of HIF-1α with HIF-1β under hypoxic conditions results in the formation of the HIF-1 transcription factor, which binds to hypoxia response elements (HREs) and activates the transcription of O2-dependent genes (according to [134]).](https://figures.cochat.ai/paper-figures/7f1eff6f4e4b425f9d8561e5e5c9be64/hypoxia-inducible-factor-1-in-physiological-and-pathophysiological-angiogenesis-figure-1.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the normal developmental setting, HIF-1α plays a dominant role throughout vasculogenesis, whereas HIF-2α contributes primarily to vessel remodeling and maturation during the later stages of vasculogenesis (the HIF switch) [25].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Characteristics of tumor vasculature include lack of stabilization by pericytes and smooth muscle cells and a lack of an arterial or venous phenotype that leads to leakage, poor blood flow and perfusion (Figure 3) [25].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Risau, W. (1997) · Nature · doi:10.1038/386671a0 · Cited by 5,727 · cited 2×
“Because the uterine environment is hypoxic it is thereby obvious that hypoxiamay be the primary stimulus of vessel formation [3, 4].”
BackgroundMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Angiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276 · cited 1×
“growth factors that activate their receptors [5, 6].”
Mechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162 · cited 1×
“Vessel formation occurs via only two basicmechanisms: vasculogenesis and angiogenesis [2].”
BackgroundActivation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653 · cited 1×
“The activation of the most prominent proangiogenic factor VEGF might be due to physiological stimuli such as hypoxia or inflammation or due to oncogene activation and tumour suppression function loss [18, 19].”
BackgroundSemenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617 · cited 1×
“Hypoxia-inducible factor-1 was first discovered as a transcription factor that regulates erythropoietin (EPO) expression in response to low oxygen levels in the blood [27, 28].”
BackgroundProgenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla, J. M., Galiano, R. D., Levine, J. P., & Gurtner, G. C. (2004) · Nature Medicine · doi:10.1038/nm1075 · Cited by 2,600
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529 · cited 1×
“For instance, tumour vessels are leakier than normal vessels, and endothelial cells growing within tumours carry genetic abnormalities [20, 21].”
BackgroundRegulation of angiogenesis by hypoxia: role of the HIF system
Pugh, C. W., & Ratcliffe, P. J. (2003) · Nature Medicine · doi:10.1038/nm0603-677 · Cited by 2,520 · cited 2×
“In conclusion, HIF-1 may regulate the expression of proangiogenic factors either directly (by binding to HREs) or indirectly (cascade effect) [84].”
BackgroundCellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1.
Semenza, G. L., Roth, P. H., Fang, H. M., & Wang, G. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31580-6 · Cited by 1,897
Holmgren, L., O'Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,878 · cited 1×
“Hypoxia is a component of tumour development and metastasis, while angiogenesis is principal for tumour growth and progression [94, 95].”
BackgroundThe unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,748
Salceda, S., & Caro, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22642 · Cited by 1,674
Hypoxia-Inducible Factor-1 (HIF-1)
Ke, Q., & Costa, M. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.027029 · Cited by 1,646
Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch
Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., & Whitelaw, M. L. (2002) · Science · doi:10.1126/science.1068592 · Cited by 1,558 · cited 1×
“In this review, we discuss the roles of HIF-1 in both physiological/pathophysiological angiogenesis and potential strategies for clinical therapy.”
BackgroundMatrix Metalloproteinases: Biologic Activity and Clinical Implications
Nelson, A. R., Fingleton, B., Rothenberg, M. L., & Matrisian, L. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1135 · Cited by 1,554 · cited 1×
“Subsequently, matrix metalloproteinases (MMPs) enhance angiogenesis through the degradation of matrix components [10].”
BackgroundLando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L., & Bruick, R. K. (2002) · Genes & Development · doi:10.1101/gad.991402 · Cited by 1,550 · cited 1×
“In this review, we discuss the roles of HIF-1 in both physiological/pathophysiological angiogenesis and potential strategies for clinical therapy.”
BackgroundRisau, W., & Flamme, I. (1995) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cb.11.110195.000445 · Cited by 1,406
Mahon, P. C., Hirota, K., & Semenza, G. L. (2001) · Genes & Development · doi:10.1101/gad.924501 · Cited by 1,385
The impact of O2 availability on human cancer
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2540 · Cited by 1,365 · cited 1×
“Under extended exposure to reduced oxygen levels, cells are able to survive through the transcriptional activation of a series of genes that participate in angiogenesis, glucose metabolism, and cell proliferation.”
BackgroundAngiopoietin-1 protects the adult vasculature against plasma leakage
Thurston, G., Rudge, J. S., Ioffe, E., Zhou, H., Ross, L., Croll, S. D., Glazer, N., Holash, J., McDonald, D. M., & Yancopoulos, G. D. (2000) · Nature Medicine · doi:10.1038/74725 · Cited by 1,297 · cited 2×
“Ang-1, which is a known natural inhibitor of vascular permeability, protects against plasma leakage, whereas Ang-2 is involved in vessel destabilisation via the detachment of smooth muscle cells and the promotion of permeabilisation [8, 9].”
BackgroundLaughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.
Ravi, R. K., Mookerjee, B., Bhujwalla, Z. M., Sutter, T. R., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · PubMed · Cited by 1,230
Jiang, B. H., Semenza, G. L., Bauer, C., & Marti, H. H. (1996) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1996.271.4.c1172 · Cited by 1,213
Hypoxia-Induced Angiogenesis: Good and Evil
Krock, B. L., Skuli, N., & Simon, M. C. (2011) · Genes & Cancer · doi:10.1177/1947601911423654 · Cited by 1,180 · cited 2×
“In contrast, the natural pO 2 levels of bone marrow, thymus, and cartilage are at or below 1% [24, 25].”
BackgroundTranscriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1
Manalo, D. J., Rowan, A., Lavoie, T., Natarajan, L., Kelly, B. D., Ye, S. Q., Garcia, J. G. N., & Semenza, G. L. (2005) · Blood · doi:10.1182/blood-2004-07-2958 · Cited by 1,154
Cold Spring Harbor Symposia on Quantitative Biology.
Berg, H. (1989) · Journal of Electroanalytical Chemistry and Interfacial Electrochemistry · doi:10.1016/0022-0728(89)87283-3 · Cited by 1,144
Wenger, R. H. (2002) · The FASEB Journal · doi:10.1096/fj.01-0944rev · Cited by 1,135
Park, J. E., Keller, G. A., & Ferrara, N. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.12.1317 · Cited by 1,122 · cited 1×
“Notably, vascular endothelial growth factor isoforms (VEGFA, VEGF-B, VEGF-C, and VEGF-D) are the primary factors that participate in angiogenesis [79], and angiogenesis initiated by hypoxia and by HIF-1 is often VEGF-dependent primarily because HIF-1 is a master stimulator of vascular endothelial growth factor.”
BackgroundOncogenic alterations of metabolism
Dang, C. V., & Semenza, G. L. (1999) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01344-9 · Cited by 1,106 · cited 1×
“Under hypoxic conditions, cells generate only 2 ATP molecules by oxygen-independent glycolysis instead of 38 ATP molecules by the oxygen-dependent tricarboxylic acid cycle (TCA) under normoxic conditions [57, 58].”
BackgroundLiu, Y., Cox, S. R., Morita, T., & Kourembanas, S. (1995) · Circulation Research · doi:10.1161/01.res.77.3.638 · Cited by 1,040
Gao, X., Wu, G., Gu, X., Fu, L., & Mei, C. (2013) · Kidney and Blood Pressure Research · doi:10.1159/000355743 · Cited by 1,035
Integration of Oxygen Signaling at the Consensus HRE
Wenger, R. H., Stiehl, D. P., & Camenisch, G. (2005) · Science's STKE · doi:10.1126/stke.3062005re12 · Cited by 1,032 · cited 1×
“Additionally, the bHLH domain of the HIF-1α/ARNT dimer is essential for DNA binding on hypoxia response elements (HREs) with the consensus sequence (G/ACGTG) in the promoters or enhancers of target genes [32].”
BackgroundMolecular mechanisms of blood vessel growth
Conway, E. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00281-9 · Cited by 1,030 · cited 3×
“Proliferating endothelial cells migrate to distant sites and then assemble as a solid cord that subsequently forms a lumen [11].”
BackgroundInfluentialEma, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y., & Fujii-Kuriyama, Y. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4273 · Cited by 1,016 · cited 1×
“In this review, we discuss the roles of HIF-1 in both physiological/pathophysiological angiogenesis and potential strategies for clinical therapy.”
BackgroundMasson, N., Willam, C., Maxwell, P. H., Pugh, C. W., & Ratcliffe, P. J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.18.5197 · Cited by 1,014 · cited 1×
“In this review, we discuss the roles of HIF-1 in both physiological/pathophysiological angiogenesis and potential strategies for clinical therapy.”
BackgroundSemenza, G. L., Nejfelt, M. K., Chi, S. M., & Antonarakis, S. E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5680 · Cited by 990
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · Genes & Development · doi:10.1101/gad.14.1.34 · Cited by 967
Raval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940
Annual Review of Medicine, Vol. 8
BEAN, W. B. (1958) · Pediatrics · doi:10.1542/peds.22.2.413 · Cited by 889
Molecular basis of the VHL hereditary cancer syndrome
Kaelin, W. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc885 · Cited by 865
Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia.
Wang, G. L., & Semenza, G. L. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80571-7 · Cited by 862
Loss of PTEN facilitates HIF-1-mediated gene expression
Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., et al. (2000) · Genes & Development · doi:10.1101/gad.14.4.391 · Cited by 840
Lu, H., Forbes, R. A., & Verma, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202487200 · Cited by 837
Selective Requirement for Src Kinases during VEGF-Induced Angiogenesis and Vascular Permeability
Eliceiri, B. P., Paul, R., Schwartzberg, P. L., Hood, J. D., Leng, J., & Cheresh, D. A. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80221-x · Cited by 813
The role of hypoxia-inducible factors in tumorigenesis
Rankin, E. B., & Giaccia, A. J. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.21 · Cited by 806 · cited 2×
“However, notably, proangiogenic activity is directly linked with HIF-dependent VEGF activation, which results in an “angiogenic switch” in growing tumour masses [96].”
BackgroundDifferential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes
Gerber, H.-P., Condorelli, F., Park, J., & Ferrara, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.38.23659 · Cited by 794
Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2.
Feldser, D. M., Agani, F. H., Iyer, N. V., Pak, B. J., Ferreira, G., & Semenza, G. L. (1999) · PubMed · Cited by 782
Maltepe, E., Schmidt, J. V., Baunoch, D., Bradfield, C. A., & Simon, M. C. (1997) · Nature · doi:10.1038/386403a0 · Cited by 781
Gu, Y.-Z., Moran, S. M., Hogenesch, J. B., Wartman, L. D., & Bradfield, C. A. (1998) · Europe PMC (PubMed Central) · Cited by 771
Wang, G., & Semenza, G. (1993) · Blood · doi:10.1182/blood.v82.12.3610.3610 · Cited by 766
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Oxygen measurements in endometrial and trophoblastic tissues during early pregnancy.
Rodesch, F., Simon, P., Donner, C., & Jauniaux, E. R. M. (1992) · PubMed · Cited by 753
Targeting the tumour vasculature: insights from physiological angiogenesis
Chung, A. S., Lee, J., & Ferrara, N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2868 · Cited by 752 · cited 3×
“Additionally, physiological angiogenesis such as that which occurs during embryonic development or wound healing seems to be dependent on VEGF signalling, whereas tumour angiogenesis adopts the ability to shift its dependence from VEGF to other proangiogenic pathways, for example, through the recruitment of myeloid ce…”
BackgroundHigh-resolution genome-wide mapping of HIF-binding sites by ChIP-seq
Schödel, J., Oikonomopoulos, S., Ragoussis, J., Pugh, C. W., Ratcliffe, P. J., & Mole, D. R. (2011) · Blood · doi:10.1182/blood-2010-10-314427 · Cited by 724 · cited 1×
“Analyses of proangiogenic genes revealed the presence of HREs within the promoters of some genes [85, 86].”
BackgroundHewitson, K. S., McNeill, L. A., Riordan, M. V., Tian, Y.-M., Bullock, A. N., Welford, R. W., Elkins, J. M., Oldham, N. J., Bhattacharya, S., Gleadle, J. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200273200 · Cited by 719 · cited 1×
“In this review, we discuss the roles of HIF-1 in both physiological/pathophysiological angiogenesis and potential strategies for clinical therapy.”
BackgroundInhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression
Makino, Y., Cao, R., Svensson, K., Bertilsson, G., Asman, M., Tanaka, H., Cao, Y., Berkenstam, A., & Poellinger, L. (2001) · Nature · doi:10.1038/35107085 · Cited by 705 · cited 1×
“In this review, we discuss the roles of HIF-1 in both physiological/pathophysiological angiogenesis and potential strategies for clinical therapy.”
BackgroundTumour suppression by the human von Hippel-Lindau gene product
Iliopoulos, O., Kibel, A., Gray, S., & Kaelin, W. G. (1995) · Nature Medicine · doi:10.1038/nm0895-822 · Cited by 703
Semenza, G. L. (2007) · Science · doi:10.1126/science.1147949 · Cited by 703 · cited 1×
“Thus, the vasculature network plays a crucial role in delivering oxygen particles (O 2 ), nutrients, and other molecules within the entire human body [22].”
BackgroundVascular endothelial–cadherin is an important determinant of microvascular integrity invivo
Corada, M., Mariotti, M., Thurston, G., Smith, K., Kunkel, R., Brockhaus, M., Lampugnani, M. G., Martin-Padura, I., Stoppacciaro, A., Ruco, L., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9815 · Cited by 676
Kallio, P. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.22.6573 · Cited by 666
Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression
Semenza, G. L. (2000) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230091169186 · Cited by 654 · cited 1×
“The malignant transformation of cells may cause a whole range of genetic alterations that block the ubiquitination and proteasomal degradation of HIF-1α [84, 98].”
BackgroundEliceiri, B. P., & Cheresh, D. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6869 · Cited by 649
Transcription Factor HIF-1 Is a Necessary Mediator of the Pasteur Effect in Mammalian Cells
Seagroves, T. N., Ryan, H. E., Lu, H., Wouters, B. G., Knapp, M., Thibault, P., Laderoute, K., & Johnson, R. S. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.10.3436-3444.2001 · Cited by 634 · cited 1×
“Under hypoxic conditions, cells generate only 2 ATP molecules by oxygen-independent glycolysis instead of 38 ATP molecules by the oxygen-dependent tricarboxylic acid cycle (TCA) under normoxic conditions [57, 58].”
BackgroundTransactivation and Inhibitory Domains of Hypoxia-inducible Factor 1α
Jiang, B.-H., Zheng, J. Z., Leung, S. W., Roe, R., & Semenza, G. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.31.19253 · Cited by 629 · cited 1×
“In this review, we discuss the roles of HIF-1 in both physiological/pathophysiological angiogenesis and potential strategies for clinical therapy.”
Background(2003) · PubMed · Cited by 624
Why are tumour blood vessels abnormal and why is it important to know?
Nagy, J. A., Chang, S.-H., Dvorak, A. M., & Dvorak, H. F. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604929 · Cited by 611 · cited 1×
“For instance, tumour vessels are leakier than normal vessels, and endothelial cells growing within tumours carry genetic abnormalities [20, 21].”
BackgroundKelly, B. D., Hackett, S. F., Hirota, K., Oshima, Y., Cai, Z., Berg-Dixon, S., Rowan, A., Yan, Z., Campochiaro, P. A., & Semenza, G. L. (2003) · Circulation Research · doi:10.1161/01.res.0000102937.50486.1b · Cited by 611 · cited 1×
“Due to the upregulation of PlGF and VEGF expression after AdCA5 treatment, both genes acted synergistically, which led to neovascularisation of the retina [117].”
BackgroundHypoxia-Inducible Factor 1 and Cardiovascular Disease
Semenza, G. L. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170322 · Cited by 608 · cited 3×
“The state when the O 2 level decreases relative to physiological levels (characteristic for particular tissues) is called hypoxia [1].”
BackgroundInfluentialThe mammalian basic helix–loop–helix/PAS family of transcriptional regulators
Kewley, R. J., Whitelaw, M. L., & Chapman-Smith, A. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(03)00211-5 · Cited by 589 · cited 1×
“HIF-1 consists of two different subunits, α and β (also known as aryl hydrocarbon nuclear receptor translocator (ARNT)); both subunits are members of the basic helix-loop-helix Per-Arnt-Sim (bHLHPAS) transcription factor family [29, 30].”
BackgroundRajagopalan, S., Mohler, E. R., Lederman, R. J., Mendelsohn, F. O., Saucedo, J. F., Goldman, C. K., Blebea, J., Macko, J., Kessler, P. D., Rasmussen, H. S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000093398.16124.29 · Cited by 574
Mole, D. R., Blancher, C., Copley, R. R., Pollard, P. J., Gleadle, J. M., Ragoussis, J., & Ratcliffe, P. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m901790200 · Cited by 552
Activation of Hypoxia-inducible Factor-1; Definition of Regulatory Domains within the α Subunit
Pugh, C. W., O'Rourke, J. F., Nagao, M., Gleadle, J. M., & Ratcliffe, P. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.17.11205 · Cited by 532 · cited 1×
“In this review, we discuss the roles of HIF-1 in both physiological/pathophysiological angiogenesis and potential strategies for clinical therapy.”
BackgroundLederman, R. J., Mendelsohn, F. O., Anderson, R. D., Saucedo, J. F., Tenaglia, A. N., Hermiller, J. B., Hillegass, W. B., Rocha-Singh, K., Moon, T. E., Whitehouse, M., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08937-7 · Cited by 511
YC-1: A Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1
Yeo, E.-J., Chun, Y.-S., Cho, Y.-S., Kim, J., Lee, J.-C., Kim, M.-S., & Park, J.-W. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.7.516 · Cited by 476 · cited 4×
“For instance, bortezomib and amphotericin B functionally inhibit HIF-1𝛼, thereby preventing p300 recruitment by enhancing the interaction between FIH-1 and the HIF-1𝛼 C-terminal transactivation domain (C-TAD) [127, 128].”
BackgroundInfluentialProline hydroxylation and gene expression
Kaelin, W. G. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.74.082803.133142 · Cited by 468 · cited 1×
“In this review, we discuss the roles of HIF-1 in both physiological/pathophysiological angiogenesis and potential strategies for clinical therapy.”
BackgroundRegulation of angiogenesis by hypoxia-inducible factor 1
Hirota, K., & Semenza, G. L. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.12.003 · Cited by 464 · cited 1×
“Therefore, hypoxia-induced angiogenesis may be a successful strategy [115].”
BackgroundBroad targeting of angiogenesis for cancer prevention and therapy
Wang, Z., Dabrosin, C., Yin, X., Fuster, M. M., Arreola, A., Rathmell, W. K., Generali, D., Nagaraju, G. P., El-Rayes, B., Ribatti, D., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.01.001 · Cited by 464 · cited 1×
“A loss of stabilisation with pericytes and smooth muscle cells and a lack of an arterial and venous phenotype lead to leakage, poor blood flow, and perfusion [109, 110].”
BackgroundGreijer, A., van der Groep, P., Kemming, D., Shvarts, A., Semenza, G., Meijer, G., van de Wiel, M., Belien, J., van Diest, P., & van der Wall, E. (2005) · The Journal of Pathology · doi:10.1002/path.1778 · Cited by 440
Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., & Klausner, R. D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00044-2 · Cited by 432
Kallio, P. J., Pongratz, I., Gradin, K., McGuire, J., & Poellinger, L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5667 · Cited by 415
Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes
Schofield, C. J., & Zhang, Z. (1999) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(99)00036-6 · Cited by 408 · cited 2×
“Asmentioned above, PHDs require O 2 , Fe(II), and 2-oxoglutarate (2-OG) for their enzymatic activity [50, 51].”
BackgroundTakeda, K., Ho, V. C., Takeda, H., Duan, L.-J., Nagy, A., & Fong, G.-H. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00425-06 · Cited by 401
Lum, D. H., Kuwabara, P. E., Zarkower, D., & Spence, A. M. (2000) · Genes & Development · doi:10.1101/gad.853700 · Cited by 391
PR39, a peptide regulator of angiogenesis
Li, J., Post, M., Volk, R., Gao, Y., Li, M., Metais, C., Sato, K., Tsai, J., Aird, W., Rosenberg, R. D., et al. (2000) · Nature Medicine · doi:10.1038/71527 · Cited by 386 · cited 1×
“Therefore, angiogenesis can be induced in the postinfarcted myocardium of transgenic mice [124].”
BackgroundAngiogenesis Ischemic and Neoplastic Disorders
Semenza, G. L. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152418 · Cited by 386 · cited 3×
“Current studies have indicated that hypoxia and HIF1 expression in adult organisms may contribute to angiogenesis in the following ways: by transcriptionally activating several angiogenic genes and their receptors (VEGF, PlGF, PDGFB, ANGPT1, and ANGPT2) [76, 77]; by regulating proangiogenic chemokines and receptors (S…”
BackgroundControl of cell lineage-specific development and transcription by bHLH-PAS proteins
Crews, S. T. (1998) · Genes & Development · doi:10.1101/gad.12.5.607 · Cited by 347
Regulation of Metabolism by Hypoxia-Inducible Factor 1
Semenza, G. L. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010678 · Cited by 342
ARNT-Deficient Mice and Placental Differentiation
Kozak, K. R., Abbott, B., & Hankinson, O. (1997) · Developmental Biology · doi:10.1006/dbio.1997.8758 · Cited by 328 · cited 2×
“Mouse model studies have demonstrated the participation of both HIF-1 dimer subunits in vasculogenesis [69, 70].”
BackgroundElson, D. A., Thurston, G., Huang, L. E., Ginzinger, D. G., McDonald, D. M., Johnson, R. S., & Arbeit, J. M. (2001) · Genes & Development · doi:10.1101/gad.914801 · Cited by 299
Negative and positive regulation of HIF-1: A complex network
Bárdos, J. I., & Ashcroft, M. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.05.001 · Cited by 285 · cited 1×
“In eukaryotic cells, hypoxia-inducible factor-1 (HIF-1) is a primary transcriptional mediator of the hypoxic response and master regulator of O 2 homeostasis [26].”
BackgroundThe Pathophysiology of Angiogenesis
Polverini, P. J. (1995) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/10454411950060030501 · Cited by 267 · cited 1×
“Angiogenesis occurs in physiological states such as embryonic development, wound healing, or vessel penetration into avascular regions and in pathological states such as solid tumours formation, eye diseases, or chronic inflammatory disorders such as rheumatoid arthritis, psoriasis, and periodontitis [16, 17].”
BackgroundSkuli, N., Liu, L., Runge, A., Wang, T., Yuan, L., Patel, S., Iruela-Arispe, L., Simon, M. C., & Keith, B. (2009) · Blood · doi:10.1182/blood-2008-12-193581 · Cited by 255
Functional Upregulation of the Vascular Endothelial Growth Factor Receptor KDR by Hypoxia
Waltenberger, J., Mayr, U., Pentz, S., & Hombach, V. (1996) · Circulation · doi:10.1161/01.cir.94.7.1647 · Cited by 253
Hypoxia-Inducible Factors 1α and 2α Regulate Trophoblast Differentiation
Cowden Dahl, K. D., Fryer, B. H., Mack, F. A., Compernolle, V., Maltepe, E., Adelman, D. M., Carmeliet, P., & Simon, M. C. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.23.10479-10491.2005 · Cited by 228
Diez, H., Fischer, A., Winkler, A., Hu, C.-J., Hatzopoulos, A. K., Breier, G., & Gessler, M. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.09.009 · Cited by 224 · cited 1×
“Under in vitro conditions, HIF-1α promotes the arterial differentiation of endothelial progenitor cells (EPCs) over venous differentiation by regulating the expression of genes that inhibit the venous specification factor Coup-TFII (Hey2 and delta-like ligand 4 (DII4)) [67].”
BackgroundHIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O2 levels
Masson, N., & Ratcliffe, P. J. (2003) · Journal of Cell Science · doi:10.1242/jcs.00655 · Cited by 215 · cited 1×
“In this review, we discuss the roles of HIF-1 in both physiological/pathophysiological angiogenesis and potential strategies for clinical therapy.”
BackgroundRajagopalan, S., Olin, J., Deitcher, S., Pieczek, A., Laird, J., Grossman, P. M., Goldman, C. K., McEllin, K., Kelly, R., & Chronos, N. (2007) · Circulation · doi:10.1161/circulationaha.106.607994 · Cited by 187
Multilineage embryonic hematopoiesis requires hypoxic ARNT activity
Adelman, D. M., Maltepe, E., & Simon, M. C. (1999) · Genes & Development · doi:10.1101/gad.13.19.2478 · Cited by 185 · cited 1×
“In contrast, HIF-1β enhances the differentiation of hemangioblasts frommesodermal progenitors [68].”
BackgroundGarcía-Maceira, P., & Mateo, J. (2009) · Oncogene · doi:10.1038/onc.2008.398 · Cited by 185
Shyu, K.-G., Wang, M.-T., Wang, B.-W., Chang, C.-C., Leu, J.-G., Kuan, P., & Chang, H. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00259-6 · Cited by 185
Mie Lee, Y., Kim, S.-H., Kim, H.-S., Jin Son, M., Nakajima, H., Jeong Kwon, H., & Kim, K.-W. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02787-0 · Cited by 165
Inhibition of endogenous HIF inactivation induces angiogenesis in ischaemic skeletal muscles of mice
Milkiewicz, M., Pugh, C. W., & Egginton, S. (2004) · The Journal of Physiology · doi:10.1113/jphysiol.2004.069757 · Cited by 165 · cited 1×
“The delivery of small molecules such as an iron chelator (DFO) or 2-OG analogue (Noxalylglycine) may inhibit the enzyme activity [121, 122].”
BackgroundSpan, P. N., & Bussink, J. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.10.002 · Cited by 163 · cited 1×
“A loss of stabilisation with pericytes and smooth muscle cells and a lack of an arterial and venous phenotype lead to leakage, poor blood flow, and perfusion [109, 110].”
BackgroundShin, D. H., Chun, Y.-S., Lee, D. S., Huang, L. E., & Park, J.-W. (2008) · Blood · doi:10.1182/blood-2007-11-120576 · Cited by 162 · cited 4×
“For instance, bortezomib and amphotericin B functionally inhibit HIF-1𝛼, thereby preventing p300 recruitment by enhancing the interaction between FIH-1 and the HIF-1𝛼 C-terminal transactivation domain (C-TAD) [127, 128].”
BackgroundInfluentialAdaptive Myogenesis under Hypoxia
Yun, Z., Lin, Q., & Giaccia, A. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.8.3040-3055.2005 · Cited by 146 · cited 1×
“In contrast, the natural pO 2 levels of bone marrow, thymus, and cartilage are at or below 1% [24, 25].”
BackgroundSrinivas, V., Zhang, L.-P., Zhu, X.-H., & Caro, J. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0878 · Cited by 140
Endothelial–perivascular cell signaling in vascular development: lessons from knockout mice
Lindahl, P., Hellström, M., Kalén, M., & Betsholtz, C. (1998) · Current Opinion in Lipidology · doi:10.1097/00041433-199810000-00004 · Cited by 138 · cited 1×
“Other factors such as Ang-1, PDGF-BB (plateletderived growth factor BB), and PDGFR (platelet-derived growth factor receptor) participate in thematuration of blood vessels [8, 15].”
BackgroundFunctional Analysis of Hypoxia-inducible Factor-1α-mediated Transactivation
Ruas, J. L., Poellinger, L., & Pereira, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205051200 · Cited by 137 · cited 1×
“In this review, we discuss the roles of HIF-1 in both physiological/pathophysiological angiogenesis and potential strategies for clinical therapy.”
BackgroundPatel, T., KIMURA, H., WEISS, C., Semenza, G. L., & Hofmann, L. V. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.05.002 · Cited by 134
HIF-Dependent Hematopoietic Factors Regulate the Development of the Embryonic Vasculature
Ramírez‐Bergeron, D. L., Runge, A., Adelman, D. M., Gohil, M., & Simon, M. C. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.04.018 · Cited by 125
Flavopiridol, An Inhibitor of Transcription: Implications, Problems and Solutions
Blagosklonny, M. V. (2004) · Cell Cycle · doi:10.4161/cc.3.12.1278 · Cited by 121 · cited 1×
“This synthetic flavonoid, which is derived from an alkaloid Indian plant, was found to be a potent inhibitor of the transcription of HIF-1α and of many other genes involved in cell cycle arrest [132, 133].”
BackgroundThe use of dioxygen by HIF prolyl hydroxylase (PHD1)
McNeill, L. A., Hewitson, K. S., Gleadle, J. M., Horsfall, L. E., Oldham, N. J., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Schofield, C. J. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00219-6 · Cited by 116 · cited 1×
“In this review, we discuss the roles of HIF-1 in both physiological/pathophysiological angiogenesis and potential strategies for clinical therapy.”
BackgroundRecent agents targeting HIF‐1α for cancer therapy
Hu, Y., Liu, J., & Huang, H. (2013) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24390 · Cited by 113
Selective induction of integrin βi by hypoxia‐inducible factor: implications for wound healing
Keely, S., Glover, L. E., MacManus, C. F., Campbell, E. L., Scully, M. M., Furuta, G. T., & Colgan, S. P. (2008) · The FASEB Journal · doi:10.1096/fj.08-125344 · Cited by 110
Liu, X., Wang, J., Ji, X., Yu, S. P., & Wei, L. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt499 · Cited by 103 · cited 1×
“Thus, the transplantation of DMOG-treated BMSCs reduced heart infarction size and promoted angiogenesis in the ischaemic region [123].”
BackgroundYuan, C., Wang, P., Zhu, L., Dissanayaka, W. L., Green, D. W., Tong, E. H. Y., Jin, L., & Zhang, C. (2014) · Tissue Engineering Part A · doi:10.1089/ten.tea.2014.0058 · Cited by 101
Hypoxia of endothelial cells leads to MMP-2-dependent survival and death
Ben-Yosef, Y., Miller, A., Shapiro, S., & Lahat, N. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00079.2005 · Cited by 96 · cited 1×
“Metalloproteinase 2 (MMP-2) expression has been shown to be enhanced by HIF-1α [88].”
BackgroundA role for cadherins in cellular signaling and differentiation
Knudsen, K. A., Frankowski, C., Johnson, K. R., & Wheelock, M. J. (1998) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(1998)72:30/31+<168::aid-jcb21>3.0.co;2-v · Cited by 88
Newcomb, E. W., Ali, M., Schnee, T., Li, L., Lukyanov, Y., Fowkes, M. E., Miller, D. C., & Zagzag, D. (2005) · Neuro-Oncology · doi:10.1215/s1152851704000997 · Cited by 75
Mitchell, J. A., & Yochim, J. M. (1968) · Endocrinology · doi:10.1210/endo-83-4-701 · Cited by 74 · cited 1×
“During the first stage of embryogenesis, before the circulatory system develops, the oxygen tension is relatively low and does not exceed 3% [65, 66].”
BackgroundRole of histone deacetylases in acute leukemia
Fenrick, R., & Hiebert, S. W. (1998) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(1998)72:30/31+<203::aid-jcb25>3.0.co;2-4 · Cited by 73
Koning, M., Werker, P. M. N., van Luyn, M. J. A., & Harmsen, M. C. (2011) · Tissue Engineering Part A · doi:10.1089/ten.tea.2010.0624 · Cited by 71
Shankar, S., Davis, R. B., Singh, K. P., Kurzrock, R., Ross, D. D., & Srivastava, R. K. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1004 · Cited by 59
HIF ‐1α and HIF ‐2α induce angiogenesis and improve muscle energy recovery
Niemi, H., Honkonen, K. M., Korpisalo, P., Huusko, J., Kansanen, E., Merentie, M., Rissanen, T. T., André, H., Pereira, T., Poellinger, L., et al. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12333 · Cited by 53
Placental Growth Factor Provides a Novel Local Angiogenic Therapy for Ischemic Cardiomyopathy
Kolakowski, S., Berry, M. F., Atluri, P., Grand, T. J., Fisher, O. Z., Moise, M. A., Cohen, J., Hsu, V., & Woo, Y.-P. J. (2006) · Journal of Cardiac Surgery · doi:10.1111/j.1540-8191.2006.00296.x · Cited by 45
Dual VEGF/VEGFR inhibition in advanced solid malignancies
Mittal, K., Koon, H. B., Elson, P. J., Triozzi, P. L., Dowlati, A., Chen, H., Borden, E. C., & Rini, B. I. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29187 · Cited by 27
Yeom, C. J., Zeng, L., Zhu, Y., Hiraoka, M., & Harada, H. (2011) · Cancers · doi:10.3390/cancers3033610 · Cited by 27 · cited 1×
“(b) Dimerisation of HIF-1α with HIF-1β under hypoxic conditions results in the formation of the HIF-1 transcription factor, which binds to hypoxia response elements (HREs) and activates the transcription of O 2 -dependent genes (according to [134]).”
BackgroundYang, C., Liu, H., & Liu, D. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1953 · Cited by 21
Zimna, A., Janeczek, A. A., Rozwadowska, N., Frączek, M., Kucharzewska, P., Ruciński, M., Miętkiewski, T., & Kurpisz, M. K. (2014) · PubMed · Cited by 9
Self-citation
Research works printed but not linked: 11
- 1998, Journal of Cellular Biochemistry, 30-31, 168
- 2005, Science's STKE, 2005
- 1998, Gene Expression, 7, 205
- 1999, Cancer Research, 59, 3915
- 2003, Cancer Research, 63, 1138
- 1992, Obstetrics and Gynecology, 80, 283
- 2015, Tissue Engineering Part A, 21
- 1997, Tumour angiogenesis, 181
- 1998, Cancer Research, 58, 1408
- 2014, Journal of Physiology and Pharmacology, 65, 193
- 2000, Nature Medicine, 61, 49
Cited by
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
“Angiogenesis also contributes to the progression of various malignant tumors such as melanoma, breast cancer (BC),(10) colorectal cancer (CRC),(11) non-small cell lung cancer (NSCLC),(12) and renal cell carcinoma (RCC).(13) The tumor is a biological tissue with rapid proliferation, vigorous metabolism, and tenacious v…”
BackgroundTong, X., Tang, R., Xiao, M., Xu, J., Wang, W., Zhang, B., Liu, J., Yu, X., & Shi, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01392-3 · Cited by 883
“Recent investigations demonstrated that Cu is closely correlated with the expression level of hypoxia-inducible factor 1α [152, 153], which stimulates angiogenesis, and neovascularization in turn induces the production of vascular endothelial growth factor [154].”
BackgroundHypoxia-Modified Cancer Cell Metabolism
Al Tameemi, W., Dale, T. P., Al-Jumaily, R. M. K., & Forsyth, N. R. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00004 · Cited by 503
Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
Teleanu, R. I., Chircov, C., Grumezescu, A. M., & Teleanu, D. M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010084 · Cited by 503
“Thus, it is safe to assume that in normal oxygen levels within cells and tissues, HIF-1α is degraded, thus inhibiting the VEGF gene and protein expression and stopping the cascade of proangiogenic factors [60].”
BackgroundHypoxia: Overview on Hypoxia-Mediated Mechanisms with a Focus on the Role of HIF Genes
Tirpe, A. A., Gulei, D., Ciortea, S. M., Crivii, C., & Berindan-Neagoe, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246140 · Cited by 438
“HIF-1α translocate into the nucleus and binds its heterodimer counterpart, HIF-1β, with consecutive generation of active HIF-1 which is ready to bind to hypoxia-responsive elements (HREs) and regulate the gene expression of various targets [16].”
Background
Metadata
- Authors
- Zimna, A., & Kurpisz, M.
- Affiliations
- Institute of Human Genetics (PL)
- Corresponding author
- Kurpisz, Maciej
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2015
- Volume
- 2015
- Pages
- 1-13
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- PMC
- PMC4471260
- OpenAlex
- W1597158509
- Cited by
- 604
- References
- 138
- Citations by year
- 2026: 40 · 2025: 66 · 2024: 88 · 2023: 78 · 2022: 67 · 2021: 79 · 2020: 64 · 2019: 45 · 2018: 22 · 2017: 28 · 2016: 23 · 2015: 3
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- BioMed Research International (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Science Centre, Poland (2012/07/N/NZ3/01687, 2014/13/B/NZ3/04646, STRATEGMED1/233624/5/NCBR/2014)
- National Centre for Research and Development (2012/07/N/NZ3/01687, 2014/13/B/NZ3/04646, STRATEGMED1/233624/5/NCBR/2014)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Keywords
- HIF-1, angiogenesis, hypoxia, vascular endothelial growth factor, placental growth factor, angiopoietins, vasculogenesis, ischemic diseases, cancer, oxygen sensing, transcriptional regulation
- MeSH terms
- Placenta Growth Factor, Hypoxia, Humans, Neovascularization, Pathologic, Pregnancy Proteins, Transcriptional Activation, Cell Hypoxia, Neovascularization, Physiologic, Vascular Endothelial Growth Factor A, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.